Ainos and ugo Launch World's First AI Nose-Enabled Service Robot Pilots in Seven Sites Across Japan's Industrial Sector
Ainos (NASDAQ:AIMD) has announced a groundbreaking partnership with ugo Inc. to launch the world's first AI Nose-enabled service robots across seven pilot sites in Japan. The robots will be deployed in pharmaceutical manufacturing, facility management, energy operations, power substations, and water treatment plants.
The AI Nose technology has demonstrated impressive accuracy rates: 80% accuracy across 22 industrial scent types in semiconductor facilities, 85% accuracy in senior care pilots, and over 90% accuracy in food and beverage testing. The company plans to deploy approximately 1,400 AI Nose units with ASE and expand to 5,000 units in Phase 1.
This initiative is part of Ainos' 90-day action plan and positions the company for a global SmellTech-as-a-Service rollout in 2026. The global electronic nose market is projected to grow from $29.79 billion in 2025 to $76.45 billion by 2032.
Ainos (NASDAQ:AIMD) ha annunciato una partnership innovativa con ugo Inc. per il lancio dei primi robot di servizio al mondo dotati di AI Nose in sette siti pilota in Giappone. I robot saranno impiegati nella produzione farmaceutica, nella gestione degli impianti, nelle operazioni energetiche, nelle sottostazioni elettriche e negli impianti di trattamento delle acque.
La tecnologia AI Nose ha dimostrato tassi di precisione impressionanti: 80% di accuratezza su 22 tipi di odori industriali nelle strutture per semiconduttori, 85% di accuratezza nei progetti pilota per l'assistenza agli anziani e oltre il 90% di accuratezza nei test alimentari e delle bevande. L'azienda prevede di distribuire circa 1.400 unità AI Nose con ASE e di espandersi a 5.000 unità nella Fase 1.
Questa iniziativa fa parte del piano d'azione di 90 giorni di Ainos e posiziona l'azienda per il lancio globale del servizio SmellTech-as-a-Service nel 2026. Il mercato globale del naso elettronico è previsto crescere da 29,79 miliardi di dollari nel 2025 a 76,45 miliardi di dollari entro il 2032.
Ainos (NASDAQ:AIMD) ha anunciado una asociación innovadora con ugo Inc. para lanzar los primeros robots de servicio del mundo equipados con AI Nose en siete sitios piloto en Japón. Los robots se desplegarán en la fabricación farmacéutica, gestión de instalaciones, operaciones energéticas, subestaciones eléctricas y plantas de tratamiento de agua.
La tecnología AI Nose ha demostrado tasas de precisión impresionantes: 80% de precisión en 22 tipos de olores industriales en instalaciones de semiconductores, 85% de precisión en proyectos piloto de cuidado de personas mayores y más del 90% de precisión en pruebas de alimentos y bebidas. La compañía planea desplegar aproximadamente 1,400 unidades AI Nose con ASE y expandirse a 5,000 unidades en la Fase 1.
Esta iniciativa forma parte del plan de acción de 90 días de Ainos y posiciona a la empresa para un despliegue global de SmellTech-as-a-Service en 2026. Se proyecta que el mercado global de narices electrónicas crecerá de
Ainos (NASDAQ:AIMD)는 ugo Inc.와 혁신적인 파트너십을 발표하며 일본 내 7개 파일럿 사이트에서 세계 최초 AI 코 센서 탑재 서비스 로봇을 출시합니다. 이 로봇들은 제약 제조, 시설 관리, 에너지 운영, 전력 변전소, 수처리 시설에 배치될 예정입니다.
AI 코 기술은 뛰어난 정확도를 보여주고 있습니다: 반도체 시설 내 22가지 산업 향기 유형에서 80% 정확도, 시니어 케어 파일럿에서는 85% 정확도, 식음료 테스트에서는 90% 이상의 정확도를 기록했습니다. 회사는 ASE와 함께 약 1,400대의 AI 코 유닛을 배치하고 1단계에서 5,000대로 확장할 계획입니다.
이번 이니셔티브는 Ainos의 90일 행동 계획의 일부로, 2026년 글로벌 SmellTech-as-a-Service 출시를 위한 기반을 마련합니다. 전 세계 전자 코 시장은 2025년 297억 9천만 달러에서 2032년 764억 5천만 달러로 성장할 것으로 예상됩니다.
Ainos (NASDAQ:AIMD) a annoncé un partenariat révolutionnaire avec ugo Inc. pour lancer les premiers robots de service au monde équipés de la technologie AI Nose sur sept sites pilotes au Japon. Ces robots seront déployés dans la fabrication pharmaceutique, la gestion des installations, les opérations énergétiques, les postes électriques et les stations de traitement de l'eau.
La technologie AI Nose a démontré des taux de précision impressionnants : 80 % de précision sur 22 types d'odeurs industrielles dans les installations de semi-conducteurs, 85 % de précision lors des pilotes de soins aux personnes âgées, et plus de 90 % de précision dans les tests alimentaires et de boissons. La société prévoit de déployer environ 1 400 unités AI Nose avec ASE et d'étendre à 5 000 unités lors de la Phase 1.
Cette initiative fait partie du plan d'action de 90 jours d'Ainos et positionne l'entreprise pour un déploiement mondial de SmellTech-as-a-Service en 2026. Le marché mondial du nez électronique devrait passer de 29,79 milliards de dollars en 2025 à 76,45 milliards de dollars d'ici 2032.
Ainos (NASDAQ:AIMD) hat eine bahnbrechende Partnerschaft mit ugo Inc. angekündigt, um die weltweit ersten Service-Roboter mit AI Nose an sieben Pilotstandorten in Japan einzusetzen. Die Roboter werden in der pharmazeutischen Produktion, der Anlagenverwaltung, Energieoperationen, Umspannwerken und Wasseraufbereitungsanlagen eingesetzt.
Die AI Nose-Technologie hat beeindruckende Genauigkeitsraten gezeigt: 80% Genauigkeit bei 22 industriellen Geruchsarten in Halbleiteranlagen, 85% Genauigkeit in Pilotprojekten zur Seniorenbetreuung und über 90% Genauigkeit bei Tests in der Lebensmittel- und Getränkeindustrie. Das Unternehmen plant, etwa 1.400 AI Nose-Einheiten mit ASE einzusetzen und in Phase 1 auf 5.000 Einheiten zu erweitern.
Diese Initiative ist Teil des 90-Tage-Aktionsplans von Ainos und positioniert das Unternehmen für eine globale Einführung von SmellTech-as-a-Service im Jahr 2026. Der globale Markt für elektronische Nasen wird voraussichtlich von 29,79 Milliarden US-Dollar im Jahr 2025 auf 76,45 Milliarden US-Dollar bis 2032 wachsen.
- Successful integration with ugo's service robots demonstrates commercial viability
- Strong validation from multiple Japanese corporate partners across high-value industrial verticals
- Impressive accuracy rates: 80-90% across different applications
- Large market opportunity with electronic nose market projected to reach $76.45B by 2032
- Clear execution roadmap with 1,400 units planned deployment expanding to 5,000 units
- Technology still in pilot phase with commercial rollout not expected until 2026
- Accuracy rates below 90% in industrial applications may need improvement
- Heavy dependence on Japanese market success for global expansion
Insights
Ainos launches first-ever smell-enabled robots across Japanese industrial sites, validating its AI Nose technology with major potential for 2026 commercialization.
Ainos (NASDAQ:AIMD) has achieved a significant technological breakthrough by deploying the world's first smell-enabled service robots across seven industrial sites in Japan. This pilot program, in partnership with robotics company ugo, represents the first real-world implementation of Ainos' proprietary AI Nose technology and Smell Language Model (SLM).
The deployment spans multiple high-value industrial verticals including pharmaceutical manufacturing, facility management, energy operations, power substations, and water treatment plants - all operated by major Japanese corporations. This diversity of implementation sites suggests strong cross-industry applicability and validation of the technology's versatility.
The technical performance metrics are particularly noteworthy. In prior validations, the AI Nose technology demonstrated
This pilot program represents just the beginning of Ainos' commercialization strategy. The company has outlined plans for substantially larger deployments, including approximately 1,400 AI Nose units with ASE, expanding to approximately 5,000 units in Phase 1. The company is targeting 2026 for large-scale rollout of its SmellTech-as-a-Service model, creating a recurring revenue stream through subscription-based scent analytics.
The market opportunity appears substantial, with the electronic nose market projected to grow from
This development represents a fundamental expansion in robotic perception capabilities. By adding olfactory sensing to existing visual and auditory capabilities, Ainos is potentially opening new industrial applications for robots in areas like predictive maintenance, environmental monitoring, and quality control.
Seven-Site Pilot Spanning Pharma, Facility Management, Energy and Utilities to Validate AI Nose as Next-Gen Industrial AI at Scale
Robots Gain a New Sense: AI Nose Leverages Smell Language Model for Smart Scent Analytics
SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 22, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-driven scent digitization, today announced that ugo, Inc. ("ugo"), its first robotic partner, will pilot-deploy the world's first service robots equipped with a sense of smell powered by AI Nose at seven sites across Japan.
These robots, now empowered with a new sensory modality, will operate in pharmaceutical manufacturing, facility management, energy operations, power substations, and water treatment plants, at sites operated by leading Japanese corporations. This marks a historic milestone in robotic perception, blending olfactory sensing with industrial AI.
"This is a big step forward in the age of sensory AI," said Eddy Tsai, Chairman, President, and CEO of Ainos. "By giving robots the sense of smell, we are redefining how machines perceive and respond to the world. The pilot program is a great start to our 90-day roadmap. It positions us for large-scale rollout and SmellTech-as-a-Service commercialization in 2026."
As a leading service robot company in Japan, ugo's robots are already deployed in airports, data centers, factories, and corporate campuses across Japan. ugo robots with AI Nose will enable intelligent facility inspection, predictive maintenance, and environmental alerts, leveraging Ainos' proprietary smell language model (SLM) and Smell ID data insights.
"We are very honored. This is a major validation of our SmellTech model and represents strong interest from leading Japanese corporates across pharmaceuticals, energy, smart infrastructure, and utilities, each representing a high-value industrial vertical," said Mr. Eddy Tsai. "To be trusted by leading Japanese enterprises for this pilot program is a testament to the reliability and value of AI Nose. Investors should see this as a sign of strong progress, long-term scalability, and the credibility of our execution."
These seven-site pilots shortly follow Ainos and ugo's completed software and hardware integration, underscoring Ainos' execution and growing industrial momentum. Over the past few months, Ainos has secured strategic partnerships with ASE Technology Holding, Kenmec Mechanical Engineering Co., Ltd., and Solomon Technology Corporation to deploy AI Nose in semiconductor, automation, and smart-factory environments.
Ainos is fully committed to its 90-day action plan to accelerate growth and enhance long-term shareholder value. Today's pilot launch represents a major execution milestone. As part of the 90-day plan, Ainos also plans to complete pilot deployment of approximately 1,400 AI Nose units with ASE and kick off Phase 1 expansion to approximately 5,000 units.
In prior validations, AI Nose delivered approximately
The global electronic nose market is projected to grow from USD 29.79 billion in 2025 to USD 76.45 billion by 2032, with industrial applications representing the largest demand segment. Japan is a pivotal launchpad for Ainos' robotic project as it ranks second in global robot deployment.
As part of Ainos' SmellTech-as-a-Service model, customers will gain access to subscription-based scent analytics, predictive alerts, and digital Smell ID profiles, turning previously invisible scent signals into actionable, revenue-generating intelligence.
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.
About Ainos, Inc.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
About ugo, Inc.
ugo, Inc. is a Japanese robotics manufacturer that specializes in business DX robots that combine remote operation and automatic control via AI. They are designed to flexibly respond to different facilities and tasks at each site, such as security, inspection, and guidance. In business areas where labor shortages are serious, ugo supports the continuity and efficiency of operations, as well as the realization of digital transformation, not as a replacement for people but as a "partner that works with people." To lean more, visit https://corp.ugo.plus.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the accuracy rate of Ainos (NASDAQ:AIMD) AI Nose technology in different applications?
How many AI Nose units does Ainos (NASDAQ:AIMD) plan to deploy in Phase 1?
What is the projected size of the global electronic nose market by 2032?
Where will Ainos (NASDAQ:AIMD) deploy its AI Nose-enabled service robots in Japan?
When does Ainos (NASDAQ:AIMD) plan to launch its global SmellTech-as-a-Service rollout?
